Table 1.

Clinicopathological and molecular characteristics of this study.

Clinicopathologic characteristics	Number of patients, N (%) (N=4028)	RNF43 mut, N (%) (N=282)	RNF43 wild-type, N (%) (N=3746)
Age(median 57.94, range 13–95)
Young (years <50)	1321 (32.80%)	83 (29.43%)	1238 (33.05%)
Intermediate (<70 years ≥50)	1688 (41.91%)	103 (36.52%)	1585 (42.31%)
Elder (years≥70)	991 (24.60%)	95 (33.69%)	896 (23.92%)
NA	28 (0.70%)	1 (0.35%)	27 (0.72%)
Gender
Female	1895 (47.05%)	149 (52.84%)	1746 (46.61%)
Male	2071 (51.42%)	118 (41.84%)	1953 (52.14%)
NA	62 (1.54%)	15 (5.32%)	47 (1.25%)
Primary tumor location
Right	972 (24.13%)	147 (52.13%)	825 (22.02%)
Left	2103 (52.21%)	69 (24.47%)	2034 (54.30%)
NA	953 (23.66%)	66 (23.40%)	887 (23.68%)
TNM stage
I	435 (10.80%)	38 (13.48%)	397 (10.60%)
II	769 (19.09%)	91 (32.27%)	678 (18.10%)
III	1252 (31.08%)	77 (27.30%)	1175 (31.37%)
IV	1400 (34.76%)	56 (19.86%)	1344 (35.88%)
NA	172 (4.27%)	20 (7.09%)	152 (4.06%)
TUMOR_GRADE
Well differentiated	525 (13.03%)	45 (15.96%)	480 (12.81%)
Moderately differentiated	1370 (34.01%)	63 (22.34%)	1307 (34.89%)
Moderate poorly differentiated	114 (2.83%)	10 (3.55%)	104 (2.78%)
Poorly differentiated	355 (8.81%)	58 (20.57%)	297 (7.93%)
NA	1664 (41.31%)	106 (37.59%)	1558 (41.59%)
TMB
TMB-H	921 (22.86%)	198 (70.21%)	723 (19.30%)
TMB-L	2765 (68.64%)	67 (23.76%)	2698 (72.02%)
NA	342 (8.49%)	17 (6.03%)	325 (8.68%)
MSI
MSI-H	296 (7.35%)	138 (48.94%)	158 (4.22%)
MSS	2858 (70.95%)	92 (32.62%)	2766 (73.84%)
NA	874 (21.70%)	52 (18.44%)	822 (21.94%)
BRAF status
BRAF mut	363 (9.01%)	96 (34.04%)	267 (7.13%)
BRAF wild-type	3665 (90.99%)	186 (65.96%)	3479 (92.87%)
BRAF mutation types
Class 1	256 (6.36%)	86 (30.50%)	170 (4.54%)
Class 2	9 (0.22%)	0 (0.00%)	9 (0.24%)
Class 3	40 (0.99%)	0 (0.00%)	40 (1.07%)
NA	58 (1.44%)	10 (3.55%)	48 (1.28%)